Brand dynamics

Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health

The Top 100 Chinese Pharmaceutical Companies of 2022 Announced, with Health Spring Among the Top 100

Published Time:

2023-11-21

On November 17, 2023, the highly anticipated "2023 China Pharmaceutical Industry Development Conference" was held in Beijing, the capital. The event was jointly hosted by the Ministry of Industry and Information Technology, the Beijing Municipal People's Government, the National Health Commission, the State-owned Assets Supervision and Administration Commission of the State Council, the State Administration of Traditional Chinese Medicine, and the National Medical Products Administration. At the conference, the highly anticipated 2022 Top 100 Chinese Pharmaceutical Companies list was released. Healthy Yuan and Lizhu Group were both on the list, ranking 65th and 21st respectively. Healthy Yuan is a newcomer to the 2022 Top 100 list, jumping from 103rd in 2021 to 65th in 2022.

 
 
As outstanding representatives of the Chinese pharmaceutical industry, the top 100 companies are models and pillars of the industry's vigorous development. In 2022, a year full of challenges, the pharmaceutical industry demonstrated remarkable resilience, enabling the top 100 companies to achieve a total main business income exceeding one trillion yuan, reaching 1033.21 billion yuan. At the same time, after a brief decline in 2020, the entry threshold for the top 100 companies has increased for two consecutive years, increasing by 8% year-on-year in 2022 to 3.39 billion yuan. This achievement signifies the continuous improvement of the overall strength and competitiveness of companies in the industry. Healthy Yuan and Lizhu Group's inclusion in the 2022 Top 100 Chinese Pharmaceutical Companies list is a high recognition of their business strength and operational development.
 
In the first three quarters of 2023, Healthy Yuan achieved operating revenue of 12.651 billion yuan and net profit of 1.084 billion yuan; Lizhu Group achieved operating revenue of 9.655 billion yuan and net profit of 1.602 billion yuan. Behind the steady growth in performance lies the guidance of the company's development strategy and its commitment to research and development innovation.
In recent years, Healthy Yuan has adhered to the development strategy of "innovative drugs + high-end complex preparations," continuously increasing investment in research and development. Relying on solid innovative R&D capabilities and diversified strategic layout, it has established market competitive advantages in multiple pharmaceutical segments. In the respiratory field, several of Healthy Yuan's products have entered the "good news" stage, such as inhaled budesonide suspension, levosalbutamol hydrochloride nebulization solution, and formoterol fumarate inhalation solution, all of which are expected to be approved for market launch this year; fluticasone propionate nebulization suspension and salmeterol/fluticasone inhalation powder are also undergoing registration.
In addition to independent research and development, Healthy Yuan has also introduced multiple innovative drugs into its R&D pipeline, further strengthening its core competitiveness. Among them, TG-1000, a collaborative project with Taijing Biology, has started Phase III clinical trials. TG-1000 is an innovative PA nuclease inhibitor that can effectively inhibit both influenza A and B viruses; an exclusive license agreement has been signed with FermiTech for the analgesic new drug FZ008-145 in Greater China. This drug is a highly selective second-generation Nav1.8 (voltage-gated sodium channel 1.8) inhibitor with superior efficacy and non-addictive analgesia advantages. An IND application was submitted to the CDE in October this year.
Innovation is the eternal theme of the pharmaceutical industry's development. For future R&D planning, Healthy Yuan will firmly adhere to the dual-engine driving strategy of "innovative drugs + high-barrier complex preparations," focusing on advantageous therapeutic areas such as respiratory diseases, digestion, mental health, and assisted reproduction, steadily advancing various R&D work, and further establishing the company's position as an innovative pharmaceutical company.

Appendix:

Top 100 Chinese Pharmaceutical Companies in 2022

1
China National Pharmaceutical Group Corporation
2
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
3
Guangzhou Pharmaceutical Holdings Limited
4
China Resources Pharmaceutical Holdings Co., Ltd.
5
Qilu Pharmaceutical Group Co., Ltd.
6
Shanghai Pharmaceutical (Group) Co., Ltd.
7
Shijiazhuang Pharmaceutical Group Co., Ltd.
8
Zhejiang Huahai Pharmaceutical Co., Ltd.
9
China Yunda Group Co., Ltd.
10
Yangtze River Pharmaceutical Group Co., Ltd.
11
Jiangxi Jimen Kexin Group Co., Ltd.
12
Bayer Healthcare LLC
13
Zhengda Tianqing Pharmaceutical Group Co., Ltd.
14
Jiangsu Hengrui Medicine Co., Ltd.
15
Novo Nordisk (China) Pharmaceutical Co., Ltd.
16
Sanofi (China) Investment Co., Ltd.
17
Pfizer Pharmaceutical Co., Ltd.
18
Sichuan Kelun Pharmaceutical Co., Ltd.
19
AstraZeneca Pharmaceutical Co., Ltd.
20
Weigao Group Co., Ltd.
21
Lizhu Pharmaceutical Group Co., Ltd.
22
Xi'an Janssen Pharmaceutical Co., Ltd.
23
Changchun High and New Technology Industry (Group) Co., Ltd.
24
New Hope Group Co., Ltd.
25
Shijiazhuang Yiling Pharmaceutical Co., Ltd.
26
Renfu Pharmaceutical Group Co., Ltd.
27
Zhuhai United Pharmaceutical Co., Ltd.
28
Shandong Buchang Pharmaceutical Co., Ltd.
29
Roche Pharmaceuticals (Shanghai) Ltd.
30
Merck Sharp & Dohme (Hangzhou) Pharmaceutical Co., Ltd.
31
Lunan Pharmaceutical Group Co., Ltd.
32
Wuhan Mindray Bio-Medical Electronics Co., Ltd.
33
North China Pharmaceutical Group Co., Ltd.
34
Jiangsu Haosen Pharmaceutical Group Co., Ltd.
35
Jiangsu Jichuan Holdings Group Co., Ltd.
36
Tianjin Pharmaceutical Group Co., Ltd.
37
Zhejiang Huahai Pharmaceutical Co., Ltd.
38
Prolor Biotech, Inc.
39
Novartis Pharmaceuticals (Beijing) Co., Ltd.
40
Fresenius Kabi (China) Investment Co., Ltd.
41
Shandong Xinhua Pharmaceutical Co., Ltd.
42
Zhejiang Oriental Gene Bio-products Co., Ltd.
43
Tianshili Holdings Group Co., Ltd.
44
Shenzhen Hai普瑞 Pharmaceutical Group Co., Ltd.
45
Shenzhen Dongyang Real Estate Development Co., Ltd.
46
Shenyang Sansheng Pharmaceutical Co., Ltd.
47
Zhejiang Haizheng Pharmaceutical Co., Ltd.
48
Chengdu Better Pharmaceutical Co., Ltd.
49
Yunnan Baiyao Group Co., Ltd.
50
Aikang Biotechnology (Hangzhou) Co., Ltd.
51
Sansure Biotech Inc.
52
Tianjin Redsun Pharmaceutical Co., Ltd.
53
Hangzhou Anxu Biotechnology Co., Ltd.
54
Zhejiang Pharmaceutical Co., Ltd.
55
Zhejiang Kang En Bei Pharmaceutical Co., Ltd.
56
Shijiazhuang Siyao Co., Ltd.
57
Hualy Pharmaceutical Group Co., Ltd.
58
Simcere Pharmaceutical Co., Ltd.
59
Shandong Lukang Pharmaceutical Co., Ltd.
60
Ruiyang Pharmaceutical Co., Ltd.
61
Northeast Pharmaceutical Group Co., Ltd.
62
Zhejiang Jiuzhou Pharmaceutical Co., Ltd.
63
Merck Pharmaceuticals (Jiangsu) Co., Ltd.
64
Yuxi Wosen Biotechnology Co., Ltd.
65
Joincare Pharmaceutical Group Industry Co., Ltd.
66
Hualan Biological Engineering Co., Ltd.
67
Harbin Pharmaceutical Group Co., Ltd.
68
Yuekang Pharmaceutical Group Co., Ltd.
69
Innovent Biologics (Suzhou) Co., Ltd.
70
Zhejiang Xianju Pharmaceutical Co., Ltd.
71
Jiangsu Kangyuan Pharmaceutical Co., Ltd.
72
Beijing Taide Pharmaceutical Co., Ltd.
73
Hubei Chutian Technology Co., Ltd.
74
Jiangsu Sose Biotechnology Co., Ltd.
75
Dongfulong Technology Group Co., Ltd.
76
Zhend Medical Products Co., Ltd.
77
Shanghai Chuangnuo Pharmaceutical Group Co., Ltd.
78
Shenwei Pharmaceutical Group Co., Ltd.
79
Aomei Medical Products Co., Ltd.
80
Qingfeng Pharmaceutical Group Co., Ltd.
81
Chenxin Technology Group Co., Ltd.
82
Sichuan Good Doctor Panxi Pharmaceutical Co., Ltd.
83
Yantai Green Leaf Pharmaceutical Holdings (Group) Co., Ltd.
84
Shanghai Leishi Blood Products Co., Ltd.
85
Kuaizhi Pharmaceutical Group Co., Ltd.
86
Renhe (Group) Development Co., Ltd.
87
Zhejiang Jingxin Pharmaceutical Co., Ltd.
88
Jiangsu Enhua Pharmaceutical Co., Ltd.
89
Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.
90
Shi Huida Pharmaceutical Group (Jilin) Co., Ltd.
91
Boehringer Ingelheim Pharmaceuticals (Shanghai) Co., Ltd.
92
Shandong Qidu Pharmaceutical Co., Ltd.
93
Shanxi Yaobao Investment Group Co., Ltd.
94
Baxter (China) Investment Co., Ltd.
95
China Medical Health Industry Co., Ltd.
96
Yantai Dongcheng Pharmaceutical Group Co., Ltd.
97
Shandong Jincheng Pharmaceutical Group Co., Ltd.
98
Suzhong Pharmaceutical Group Co., Ltd.
99
Shenzhen Lepu Medical Technology Co., Ltd.
100
Chengdu Kanghong Pharmaceutical Group Co., Ltd.